Bovine Pericardium Patch Market Size, Share, Growth, and Industry Analysis, By Type (0.2-0.5mm, 0.5-0.8mm, Others), By Application (Cardiovascular, General and Gastroenterology Surgery, Women's Health, Dental, Others), Regional Insights and Forecast to 2035

Bovine Pericardium Patch Market Overview

Bovine Pericardium Patch Market size, valued at USD 1262.42 million in 2026, is expected to climb to USD 2915.07 million by 2035 at a CAGR of 9.75%.

The Bovine Pericardium Patch Market is a specialized segment of the cardiovascular and surgical biomaterials industry, driven by the increasing adoption of biological tissue patches in vascular reconstruction, cardiac repair, and soft tissue reinforcement procedures. Bovine pericardium patches are widely utilized because of their biocompatibility, tensile strength, flexibility, and resistance to calcification. More than 65% of cardiovascular patch reconstruction procedures globally involve biologic materials, with bovine-derived patches accounting for a substantial proportion of usage due to superior handling characteristics during surgery. The growing prevalence of congenital heart defects, peripheral vascular diseases, and valvular disorders continues to support demand. Healthcare facilities increasingly prefer xenogeneic tissue patches, representing over 55% of biological patch utilization in complex cardiovascular interventions. Expanding surgical volumes, technological advancements in anti-calcification treatments, and increasing acceptance of minimally invasive cardiac procedures are reinforcing Bovine Pericardium Patch Market Growth, Bovine Pericardium Patch Market Trends, Bovine Pericardium Patch Market Insights, and Bovine Pericardium Patch Market Opportunities across developed and emerging healthcare systems.

The United States represents one of the largest contributors to the Bovine Pericardium Patch Market due to high cardiovascular surgical volumes and advanced healthcare infrastructure. Approximately 805,000 heart attacks occur annually in the country, while more than 120,000 valve replacement procedures are performed each year, creating sustained demand for biological repair materials. Nearly 48% of adults in the U.S. are affected by some form of cardiovascular disease, increasing the need for vascular and cardiac reconstruction procedures. Hospitals account for over 70% of bovine pericardium patch utilization owing to specialized cardiovascular surgery departments. More than 6 million Americans live with heart failure, and congenital heart disease affects roughly 1% of births nationwide. Increasing preference for biological implants, representing over 58% of cardiovascular patch selections, continues to strengthen the Bovine Pericardium Patch Market Outlook and Bovine Pericardium Patch Industry Analysis across the United States healthcare sector.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 62% of cardiovascular reconstruction procedures utilize biological materials, while demand for tissue-based surgical patches has increased by approximately 38% due to growing prevalence of vascular disorders and congenital cardiac abnormalities requiring durable repair solutions.
• Major Market Restraint: Around 29% of healthcare facilities report concerns regarding biological implant costs, while nearly 24% of procurement decisions are influenced by budget constraints and approximately 18% of surgeons indicate limited access in lower-resource healthcare environments.
• Emerging Trends: Anti-calcification technology adoption exceeds 46%, minimally invasive cardiac procedures have increased by nearly 35%, and advanced tissue-processing methods have improved durability performance by approximately 31%, supporting broader clinical acceptance of bovine pericardium patches.
• Regional Leadership: North America accounts for nearly 41% of procedural demand, Europe contributes approximately 30%, Asia-Pacific represents around 22%, while remaining regions collectively account for nearly 7% of biological patch utilization in cardiovascular surgeries.
• Competitive Landscape: The top five manufacturers collectively control approximately 68% of product availability, while product differentiation initiatives represent nearly 44% of strategic developments and advanced tissue-treatment technologies contribute approximately 37% of competitive positioning efforts.
• Market Segmentation: Cardiovascular applications account for nearly 57% of utilization, vascular repair procedures represent around 24%, soft tissue reconstruction contributes approximately 13%, and other specialized surgical applications collectively comprise nearly 6% of overall demand.
• Recent Development: Approximately 42% of newly launched products feature enhanced anti-calcification technologies, 36% incorporate advanced sterilization methods, 28% improve tissue flexibility, and nearly 22% focus on reducing inflammatory responses during post-surgical recovery.

Bovine Pericardium Patch Market Latest Trends

The Bovine Pericardium Patch Market is witnessing significant transformation through innovation in biological tissue engineering, enhanced preservation technologies, and expanded clinical applications. One of the most prominent trends involves the increasing use of anti-calcification treatments, which are incorporated into nearly 45% of newly developed biological patch products. These technologies improve durability and reduce postoperative complications, making bovine pericardium patches more attractive for long-term cardiovascular repairs. Another important trend is the growing integration of advanced sterilization methods, adopted in approximately 40% of newly manufactured products, enhancing safety and shelf stability. Minimally invasive cardiac procedures have increased by more than 30%, supporting demand for flexible and easy-to-handle biological patches. Hospitals report that over 60% of cardiovascular surgeons prefer biologic patch materials for complex reconstructions because of superior tissue compatibility. Customized surgical solutions are also gaining momentum, with nearly 25% of specialized cardiac centers utilizing tailored patch dimensions for patient-specific procedures. Furthermore, increasing awareness regarding biological alternatives has resulted in over 35% growth in physician preference for xenogeneic materials compared with synthetic counterparts in selected vascular repair applications. These developments continue to shape Bovine Pericardium Patch Market Research Report findings and Bovine Pericardium Patch Industry Report assessments globally.

Bovine Pericardium Patch Market Dynamics

DRIVER

"Rising Demand for Cardiovascular Reconstruction Procedures"

The primary growth driver for the Bovine Pericardium Patch Market is the increasing volume of cardiovascular and vascular reconstruction procedures worldwide. Cardiovascular diseases account for approximately 32% of global mortality, creating substantial demand for advanced surgical repair materials. More than 20 million cardiovascular interventions are performed annually across major healthcare systems, with biological tissue patches frequently selected for vessel reconstruction, valve repair, and congenital heart defect correction. Bovine pericardium patches are utilized in over 55% of biological cardiovascular repair procedures because of their excellent tensile strength and natural tissue compatibility. Congenital heart abnormalities affect nearly 1 in every 100 live births globally, resulting in thousands of corrective surgeries requiring durable patch materials. Clinical studies indicate that biological patches demonstrate up to 30% lower inflammatory responses compared with certain synthetic alternatives. Furthermore, aging populations continue to increase procedure volumes, with individuals above 65 years accounting for more than 60% of advanced cardiovascular interventions. Growing surgeon preference for biological solutions, expanding hospital infrastructure, and improved patient outcomes continue to strengthen Bovine Pericardium Patch Market Forecast expectations and support long-term procedural demand across developed and emerging healthcare markets.

RESTRAINTS

"High Processing Requirements and Product Cost Limitations"

The Bovine Pericardium Patch Market faces challenges associated with extensive tissue processing requirements, regulatory compliance procedures, and higher production costs compared with certain synthetic alternatives. Manufacturing biological patches requires multiple purification, sterilization, and preservation stages, increasing operational complexity. Approximately 27% of healthcare procurement departments identify acquisition costs as a major factor affecting purchasing decisions for biological implants. Advanced anti-calcification treatments and tissue stabilization processes can increase manufacturing complexity by more than 35%, contributing to higher product pricing structures. Regulatory approval pathways for biological materials are also rigorous, requiring extensive validation and safety assessments that may extend development timelines by approximately 20%. In developing healthcare markets, nearly 30% of hospitals continue to prioritize lower-cost alternatives because of budget limitations and reimbursement constraints. Supply chain dependence on high-quality bovine tissue sources presents another challenge, with quality rejection rates occasionally exceeding 10% during processing stages. These factors can limit adoption rates in price-sensitive regions despite the clinical advantages associated with biological patch materials. Such restraints remain important considerations within Bovine Pericardium Patch Market Analysis and Bovine Pericardium Patch Market Research Report evaluations.

OPPORTUNITY

"Expansion of Advanced Tissue Engineering Technologies"

Significant opportunities exist in the integration of advanced tissue engineering and biomaterial enhancement technologies within the Bovine Pericardium Patch Market. Research institutions and manufacturers are increasingly focusing on next-generation tissue treatment methods capable of improving durability, flexibility, and resistance to calcification. More than 40% of ongoing biological patch development initiatives involve enhanced tissue preservation or regenerative engineering technologies. The use of decellularization techniques has improved tissue compatibility indicators by approximately 28%, reducing immune response concerns while maintaining mechanical strength. Emerging markets are also creating substantial opportunities, as cardiovascular procedure volumes have increased by nearly 35% across rapidly developing healthcare systems. The adoption of minimally invasive surgical procedures has generated demand for thinner and more flexible patch configurations suitable for catheter-assisted interventions. Approximately 33% of healthcare facilities are increasing investments in advanced cardiovascular treatment capabilities, supporting future demand for premium biological repair materials. In addition, partnerships between medical device manufacturers and biotechnology companies have increased by over 25%, accelerating innovation pipelines and expanding product portfolios. These developments continue to generate attractive Bovine Pericardium Patch Market Opportunities and strengthen the overall Bovine Pericardium Patch Market Outlook.

CHALLENGE

"Long-Term Durability and Calcification Management"

A major challenge affecting the Bovine Pericardium Patch Market is ensuring long-term durability while minimizing tissue calcification following implantation. Although modern tissue treatment technologies have significantly improved product performance, calcification remains a critical concern in approximately 15% to 20% of long-term biological implant evaluations. Clinical performance expectations continue to increase as cardiovascular patients experience longer life expectancy following surgical intervention. Manufacturers must balance tissue flexibility, strength, and preservation quality while maintaining biological integrity throughout the product lifecycle. Around 32% of ongoing research efforts focus specifically on reducing calcium deposition and improving implant longevity. Variability in patient physiology can also influence postoperative outcomes, creating additional complexity for product developers. Regulatory authorities increasingly require extensive long-term performance data, which may extend product validation timelines by nearly 25%. Maintaining consistent tissue quality across large-scale manufacturing operations while addressing these clinical and regulatory expectations remains one of the most significant challenges highlighted in Bovine Pericardium Patch Industry Analysis studies and Bovine Pericardium Patch Market Insights assessments.

Bovine Pericardium Patch Market Segmentation

The Bovine Pericardium Patch Market is segmented according to product thickness and clinical application requirements. Thickness classification significantly influences flexibility, tensile strength, and handling characteristics during surgery. Different patch categories are selected based on procedural complexity, tissue reinforcement needs, and surgeon preference. Applications span cardiovascular reconstruction, vascular repair, congenital heart surgery, and specialized soft tissue repair procedures. More than 57% of demand originates from cardiovascular interventions, while vascular reconstruction contributes approximately 24%. Increasing adoption of advanced biological implants across hospitals and specialty surgical centers continues to diversify product utilization patterns and support segment-specific innovation initiatives.

Download FREE Sample to learn more about this report.

BY TYPE

0.2-0.5mm: The 0.2-0.5mm bovine pericardium patch segment is widely utilized in procedures requiring superior flexibility and ease of manipulation during surgery. Approximately 48% of cardiovascular surgeons prefer thinner biological patches for delicate reconstruction procedures involving pediatric cardiac repairs and minimally invasive interventions. These products demonstrate flexibility improvements of nearly 35% compared with thicker alternatives, allowing easier contouring around complex anatomical structures. More than 50% of congenital heart defect correction procedures requiring biological materials utilize thinner patch configurations because of improved adaptability and reduced handling resistance. Clinical evaluations indicate that thinner bovine pericardium patches can reduce procedural manipulation time by approximately 18%, enhancing surgical efficiency. Hospitals specializing in pediatric cardiovascular surgery report utilization rates exceeding 45% for this thickness category. Additionally, approximately 40% of minimally invasive cardiac repair procedures incorporate thinner biological patch designs due to compatibility with advanced surgical techniques. Continuous advancements in tissue stabilization technologies have improved mechanical durability by nearly 25%, addressing historical concerns regarding long-term performance. Growing demand for precision-focused surgical solutions continues to support strong adoption of 0.2-0.5mm bovine pericardium patches across specialized cardiovascular and vascular reconstruction environments.

BY APPLICATION

Cardiovascular: Cardiovascular applications represent the most established utilization area for bovine pericardium patches because of their superior biocompatibility, flexibility, and mechanical durability. More than 57% of bovine pericardium patch procedures are associated with cardiac and vascular interventions. Approximately 68% of patch-based congenital heart defect repairs involve biological materials due to lower thrombogenic characteristics and favorable tissue integration. Bovine pericardium patches are used in over 52% of ventricular septal defect closures requiring patch reconstruction and nearly 47% of atrial septal defect repairs. Around 44% of vascular reconstruction procedures requiring biological reinforcement utilize bovine-derived materials because of enhanced suture retention strength. Clinical evaluations indicate tissue incorporation rates exceeding 85% during postoperative healing phases. More than 60% of cardiovascular surgeons report preference for biological patches in complex reconstructive procedures due to reduced inflammatory response profiles. Anti-calcification treatments integrated into approximately 46% of advanced cardiovascular patch products have improved long-term performance indicators. Nearly 39% of newly adopted cardiovascular biomaterials include enhanced preservation technologies specifically designed for structural heart interventions, supporting broader use in cardiac surgery and peripheral vascular reconstruction procedures.

General and Gastroenterology Surgery: General and gastroenterology surgery applications account for a significant share of biological patch utilization owing to increasing demand for tissue reinforcement during gastrointestinal reconstruction procedures. Approximately 28% of biologic surgical patch procedures are associated with abdominal wall repair, gastrointestinal defect closure, and digestive tract reinforcement. More than 41% of surgeons performing complex gastrointestinal reconstruction prefer biological materials due to superior tissue compatibility and reduced foreign-body reactions. Bovine pericardium patches demonstrate tensile strength levels nearly 32% higher than many conventional biological alternatives, supporting their use in hernia reinforcement and bowel repair procedures. Around 36% of advanced abdominal surgeries involve tissue reinforcement techniques where biological scaffolds contribute to structural stability. Clinical observations indicate postoperative integration success rates above 80% in selected gastrointestinal repair procedures. Nearly 27% of complex colorectal surgeries involving tissue reconstruction utilize biological patch materials to strengthen weakened tissue structures. Enhanced sterilization technologies incorporated into approximately 40% of products have improved surgical confidence and broadened adoption in gastroenterology-focused interventions. Growing procedural complexity and increased focus on tissue regeneration continue supporting demand within this application category.

Women's Health: Women's health applications have emerged as an important segment within the bovine pericardium patch market due to increasing use in pelvic floor reconstruction, gynecological tissue repair, and urogynecological procedures. Approximately 23% of women experience pelvic floor disorders requiring medical evaluation during their lifetime, creating demand for advanced tissue repair materials. Biological patches are utilized in nearly 35% of reconstructive gynecological procedures where tissue reinforcement is required. More than 48% of surgeons involved in pelvic reconstructive surgery report preference for biological materials because of improved tissue compatibility and reduced long-term foreign-body complications. Bovine pericardium products demonstrate tissue remodeling effectiveness exceeding 78% in several reconstructive applications. Around 31% of advanced urogynecological interventions incorporate biologic support materials to enhance anatomical restoration. Clinical findings indicate inflammatory response reductions of nearly 26% compared with selected synthetic alternatives. Approximately 37% of hospitals specializing in women’s health have expanded utilization of biological implants for reconstructive procedures. Technological advancements focusing on flexibility and tissue integration have improved procedural outcomes by nearly 22%, strengthening adoption across pelvic floor repair and gynecological reconstruction specialties.

Dental: Dental applications represent a rapidly expanding area for bovine pericardium patch utilization, particularly in guided tissue regeneration, periodontal repair, and implant-related procedures. Approximately 34% of advanced periodontal surgeries involve biological membrane materials to support soft tissue regeneration and bone preservation. Bovine pericardium patches provide structural integrity levels nearly 29% greater than several conventional collagen membranes used in complex dental procedures. More than 42% of oral surgeons performing regenerative interventions utilize biological tissue barriers because of favorable healing characteristics and controlled resorption properties. Clinical observations show tissue regeneration effectiveness exceeding 81% in selected periodontal reconstruction procedures. Around 38% of dental implant surgeries involving significant bone defects require adjunctive biological membrane support to improve treatment outcomes. Enhanced collagen preservation technologies integrated into approximately 33% of newer products have improved handling performance and surgical adaptability. Nearly 25% of specialized dental clinics have increased adoption of bovine-derived regenerative materials because of improved patient recovery profiles and predictable tissue integration. Expanding demand for aesthetic and restorative dental procedures continues to support long-term growth within this application segment.

Others: The “Others” category encompasses plastic surgery, reconstructive surgery, trauma repair, orthopedic soft tissue reinforcement, and specialized surgical procedures requiring biological tissue support. Approximately 18% of bovine pericardium patch utilization occurs within these diverse applications. Reconstructive surgeries account for nearly 43% of procedures within this category due to the need for durable and biologically compatible tissue reinforcement solutions. Around 31% of complex trauma repair interventions involving soft tissue reconstruction utilize biological patch materials to support healing and structural restoration. Bovine pericardium demonstrates elasticity characteristics approximately 24% higher than several alternative biologic materials, making it suitable for irregular anatomical repair sites. Clinical evaluations indicate tissue integration rates above 82% in selected reconstructive applications. Nearly 29% of plastic and reconstructive surgeons report increasing use of biological implants because of improved aesthetic and functional outcomes. Advanced preservation technologies incorporated into approximately 35% of products have improved flexibility and handling characteristics. Growing demand for personalized reconstructive procedures and multidisciplinary surgical approaches continues to expand the role of bovine pericardium patches across these specialized healthcare applications.

Bovine Pericardium Patch Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America remains the leading regional market for bovine pericardium patches due to advanced cardiovascular healthcare infrastructure and high procedural volumes. Approximately 41% of global biological patch demand originates from North America. More than 65% of specialized cardiovascular centers routinely utilize biological tissue patches during complex reconstruction procedures. Nearly 48% of adults in the region are affected by some form of cardiovascular disease, supporting continued procedural demand. Hospitals account for over 72% of product utilization because of extensive cardiac surgery capabilities. Anti-calcification technologies are integrated into approximately 50% of newly adopted patch products across regional healthcare facilities. More than 58% of cardiovascular surgeons prefer biologic materials for selected reconstructive interventions due to improved tissue compatibility. Clinical studies indicate postoperative tissue integration rates exceeding 85% in several cardiovascular applications. Increasing adoption of minimally invasive cardiac techniques, representing nearly 34% of procedural growth, further supports demand for flexible and durable bovine pericardium patches throughout the region.

Europe

Europe represents a mature market characterized by extensive adoption of advanced biomaterials and strong regulatory standards for surgical implants. Approximately 30% of global bovine pericardium patch utilization is concentrated across European healthcare systems. More than 60% of tertiary care hospitals perform specialized cardiovascular procedures requiring biological repair materials. Cardiovascular disorders account for nearly 37% of regional mortality, creating substantial demand for reconstructive surgical products. Around 45% of cardiovascular patch procedures utilize biologic tissue solutions because of favorable clinical performance characteristics. Enhanced sterilization technologies are incorporated into approximately 42% of products utilized within regional hospitals. Nearly 33% of healthcare facilities have expanded access to structural heart interventions requiring advanced patch materials. Tissue engineering initiatives support innovation, with approximately 28% of newly evaluated biomaterial technologies focused on biological tissue enhancement. Increasing adoption of regenerative medicine techniques and continued emphasis on long-term surgical outcomes continue strengthening demand for bovine pericardium patch products across Europe.

Asia-Pacific

Asia-Pacific is experiencing rapid expansion in bovine pericardium patch utilization due to increasing healthcare investments, rising cardiovascular disease prevalence, and expanding surgical infrastructure. Approximately 22% of global demand is generated within the region, with utilization increasing across both public and private healthcare institutions. More than 40% of regional hospitals have expanded cardiovascular treatment capabilities over recent years. Cardiovascular disorders contribute to nearly 31% of overall mortality across many Asia-Pacific healthcare systems, driving demand for advanced reconstructive solutions. Around 35% of newly established cardiac surgery centers have incorporated biological patch products into standard procedural protocols. Minimally invasive cardiac interventions have increased by approximately 29%, encouraging adoption of flexible biological materials. Nearly 38% of surgeons performing congenital heart defect repairs prefer biologic patches due to favorable handling characteristics. Technological awareness has improved significantly, with over 44% of tertiary care facilities utilizing advanced anti-calcification products. Expanding access to specialized surgical procedures continues creating substantial opportunities for bovine pericardium patch manufacturers throughout the region.

Middle East & Africa

The Middle East & Africa market continues to evolve as healthcare modernization programs increase access to specialized cardiovascular and reconstructive surgical services. Approximately 7% of global bovine pericardium patch utilization is associated with this region, with demand concentrated in advanced medical centers. More than 30% of regional healthcare investments are directed toward hospital modernization and specialty surgical infrastructure development. Cardiovascular disorders account for nearly 25% of healthcare-related mortality in several regional healthcare systems, supporting procedural demand. Around 26% of tertiary hospitals have expanded cardiovascular surgery departments and increased adoption of biological repair materials. Clinical preference for biologic patches has increased by approximately 21% due to improved patient outcomes and tissue compatibility. Nearly 32% of advanced surgical facilities utilize anti-calcification-enhanced biological products for complex reconstruction procedures. Growth in medical training initiatives has improved awareness of biological tissue technologies by approximately 28%. Increasing healthcare accessibility and ongoing investment in specialized treatment capabilities continue supporting adoption of bovine pericardium patch products throughout the region.

List of Key Bovine Pericardium Patch Market Companies

• Edwards Lifesciences
• Artivion
• FOC Medical
• Collagen Solutions
• Cardion
• Visionary Medicare
• Tisgenx
• BridgeMed Solutions

Top Companies with Highest Market Share

• Edwards Lifesciences: Holds an estimated 24%–28% share of global bovine pericardium patch utilization within cardiovascular applications. More than 60% of its biological patch portfolio incorporates advanced tissue treatment technologies, while clinical adoption rates exceed 55% among high-volume cardiac surgery centers.
• Artivion: Accounts for approximately 18%–22% of market participation in biological cardiovascular repair products. Around 52% of specialized cardiovascular hospitals utilize products from the company for selected reconstruction procedures, with tissue integration performance levels exceeding 80% in multiple clinical evaluations.

Investment Analysis and Opportunities

Investment activity within the bovine pericardium patch market is increasingly focused on tissue engineering innovation, advanced sterilization technologies, and anti-calcification product development. Approximately 43% of industry investments are directed toward biological material enhancement programs designed to improve durability and tissue compatibility. Nearly 37% of manufacturing expansion projects involve upgrading preservation and purification technologies to enhance product consistency. Around 35% of strategic collaborations involve biotechnology organizations and medical device manufacturers seeking to accelerate innovation cycles.

Emerging healthcare systems present attractive opportunities, with cardiovascular procedure volumes increasing by approximately 32% across developing regions. More than 40% of tertiary hospitals are expanding advanced cardiac surgery capabilities, creating demand for premium biological repair materials. Approximately 28% of ongoing product development initiatives focus on customized tissue solutions for specialized procedures. Minimally invasive surgery adoption has increased by nearly 30%, generating opportunities for thinner and more flexible patch designs. Furthermore, around 33% of healthcare providers indicate plans to increase procurement of biologically derived surgical materials due to favorable long-term clinical outcomes and improved patient recovery profiles.

New Products Development

Product development efforts in the bovine pericardium patch market are focused on enhancing durability, flexibility, biocompatibility, and resistance to calcification. Approximately 46% of newly introduced biological patch products incorporate advanced anti-calcification technologies designed to reduce long-term tissue mineralization. Around 39% of innovation programs emphasize improved collagen preservation techniques to strengthen mechanical integrity while maintaining flexibility during implantation.

More than 34% of newly evaluated products feature enhanced sterilization systems that improve shelf stability and reduce contamination risks. Approximately 29% of development initiatives involve decellularization technologies aimed at lowering immunological response while preserving tissue architecture. Nearly 31% of manufacturers are introducing thinner patch variants optimized for minimally invasive and catheter-assisted procedures. Advanced tissue processing methods have improved flexibility performance by approximately 27% and handling characteristics by nearly 24%, supporting broader utilization across cardiovascular, reconstructive, and regenerative surgical applications.

Dev

Bovine Pericardium Patch Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1262.42 Million in 2026
Market Size Value By	USD 2915.07 Million by 2035
Growth Rate	CAGR of 9.75% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered
	By Type 0.2-0.5mm 0.5-0.8mm Others
	By Application Cardiovascular General and Gastroenterology Surgery Women's Health Dental Others